PMID- 27593960
OWN - NLM
STAT- MEDLINE
DCOM- 20170208
LR  - 20220311
IS  - 1875-533X (Electronic)
IS  - 0929-8673 (Linking)
VI  - 23
IP  - 34
DP  - 2016
TI  - Circulating Advanced Oxidation Protein Products as Oxidative Stress Biomarkers 
      and Progression Mediators in Pathological Conditions Related to Inflammation and 
      Immune Dysregulation.
PG  - 3862-3882
AB  - Evidence came out showing that oxidative stress has a pivotal role in development 
      and maintenance of inflammation and aberrant immune responses. Biomarkers of 
      oxidative stress may define the proportion of oxidative damage underlying 
      pathological conditions, and also foresee and monitor the possible efficacy of 
      therapeutic strategies designed to control these pathologies. New compounds, 
      which can be used as biomarkers, have been identified, and among them advanced 
      oxidation protein products (AOPPs), formed mainly by chlorinated oxidants 
      resulting from activity of myeloperoxidase. Our paper is aimed to review clinical 
      evidences concerning the valuable potential of AOPPs as biomarkers of oxidative 
      injury in development and progression of diseases and chronic conditions related 
      to inflammatory status and immune dysregulation. These pathologies include 
      metabolic syndrome, obesity, immune-mediated inflammatory diseases, 
      neurodegenerative diseases, and cancer. Due to the heterogeneity of pathologies 
      reported to be characterized by AOPP accumulation, it is evident that AOPPs are 
      not merely a marker of neutrophil activation, but at the same time AOPPs cannot 
      always be disease determinants. The data reported in this review corroborate the 
      opinion that AOPPs can be successfully used to in vitro confirm the diagnosis of 
      inflammatory and immune-mediated diseases, but at the same time evidence is that, 
      very likely due to the way through which AOPPs are formed as well as the effect 
      they can contribute to induce, AOPP values cannot be clearly reflective of their 
      involvement in the pathogenesis and in the evolution of a specific disease.
FAU - Cristani, Mariateresa
AU  - Cristani M
FAU - Speciale, Antonio
AU  - Speciale A
FAU - Saija, Antonella
AU  - Saija A
FAU - Gangemi, Sebastiano
AU  - Gangemi S
FAU - Minciullo, Paola Lucia
AU  - Minciullo PL
AD  - School and Division of Allergy and Clinical Immunology, Department of Clinical 
      and Experimental Medicine, University of Messina, Messina, Italy. 
      pminciullo@unime.it.
FAU - Cimino, Francesco
AU  - Cimino F
LA  - eng
PT  - Journal Article
PT  - Review
PL  - United Arab Emirates
TA  - Curr Med Chem
JT  - Current medicinal chemistry
JID - 9440157
RN  - 0 (Advanced Oxidation Protein Products)
RN  - 0 (Biomarkers)
RN  - 0 (Reactive Oxygen Species)
RN  - EC 1.11.1.7 (Peroxidase)
SB  - IM
MH  - Advanced Oxidation Protein Products/*blood/chemistry/metabolism
MH  - Autoimmune Diseases/blood/immunology/pathology
MH  - Biomarkers/blood
MH  - Disease Progression
MH  - Humans
MH  - Metabolic Diseases/blood/immunology/pathology
MH  - Neurodegenerative Diseases/blood/immunology/pathology
MH  - Obesity/blood/immunology/pathology
MH  - Oxidative Stress/*physiology
MH  - Peroxidase/metabolism
MH  - Reactive Oxygen Species/metabolism
EDAT- 2016/09/07 06:00
MHDA- 2017/02/09 06:00
CRDT- 2016/09/06 06:00
PHST- 2016/04/05 00:00 [received]
PHST- 2016/08/13 00:00 [revised]
PHST- 2016/08/30 00:00 [accepted]
PHST- 2016/09/07 06:00 [pubmed]
PHST- 2017/02/09 06:00 [medline]
PHST- 2016/09/06 06:00 [entrez]
AID - CMC-EPUB-78173 [pii]
AID - 10.2174/0929867323666160902154748 [doi]
PST - ppublish
SO  - Curr Med Chem. 2016;23(34):3862-3882. doi: 10.2174/0929867323666160902154748.